Table 2.
All-cause mortality according to time since diagnosis of lymphoproliferative malignancy in individuals with and without celiac disease
| Deaths in CD vs. deaths in controls | Crude | Adjusted | |||
|---|---|---|---|---|---|
| Follow-up | HR | 95% CI | HR | 95% CI | |
| Any overall | 200 vs. 351 | 1.33 | (1.12–1.59) | 1.23 | (1.02–1.48) |
| Year 1 | 159 vs. 236 | 1.89 | (1.42–2.52) | 1.76 | (1.31–2.36) |
| Years 2–5 | 26 vs. 51 | 1.11 | (0.81–1.51) | 1.09 | (0.79–1.49) |
| Years >5 | 15 vs. 64 | 1.06 | (0.77–1.47) | 0.90 | (0.64–1.26) |
| NHL* overall | 152 vs. 170 | 1.33 | (1.07–1.67) | 1.23 | (0.97–1.56) |
| Year 1 | 126 vs. 119 | 1.72 | (1.23–2.41) | 1.52 | (1.07–2.16) |
| Years 2–5 | 18 vs. 22 | 1.16 | (0.76–1.77) | 1.10 | (0.71–1.69) |
| Years >5 | 8 vs. 29 | 1.04 | (0.69–1.58) | 1.00 | (0.65–1.54) |
| Non-NHL overall | 48 vs. 181 | 1.41 | (1.03–1.94) | 1.22 | (0.87–1.71) |
| Year 1 | 33 vs. 117 | 1.58 | (0.84–2.98) | 1.34 | (0.71–2.52) |
| Years 2–5 | 8 vs. 29 | 1.47 | (0.91–2.39) | 1.27 | (0.77–2.08) |
| Years >5 | 7 vs. 35 | 1.22 | (0.68–2.17) | 1.05 | (0.55–1.99) |
HR, Hazard ratio; NHL, Non-Hodgkin lymphoma; HL, Hodgkin lymphoma, CLL, Chronic lymphatic leukemia; ALL, Acute lymphatic leukemia;
Non-NHL=Myeloma + Hodgkin lymphoma + Chronic lymphatic leukemia + Acute lymphatic leukemia.
*
For example, individuals with celiac disease + NHL were at increased risk (adjusted hazard ratio=1.23) to die from any cause compared with individuals with NHL only.
Adjustment, see methods for description